Work

A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu336.24

Authors: R. Ferraldeschi, S. Slovin, S. Hussain, F. Saad, J. Garcia, F.F. Kabbinavar, N. Uppal, N.J. Vogelzang, B.J. Poiesz, E. Gelmann, J. Picus, D. Mahadevan, S. Sundar, A. Nikapota, S. Pacey, A. Oganesian, L. Manlapaz-Espiritu, Y. Hao, H. Keer, J. de Bono

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Memorial Sloan Kettering Cancer Center, University of Liverpool, Université de Montréal, Cleveland Clinic, University of California, Los Angeles, Comprehensive Cancer Centers of Nevada, SUNY Upstate Medical University, Columbia University, Washington University in St. Louis, Nottingham City Hospital, Brighton and Sussex University Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Astex Pharmaceuticals

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1946708754

FWCI: 0.801

Cites:

Cited by: 3

Related to: 10